Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carotid stent reimbursement hurdles?

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Cordis (Precise) could run into difficulties overturning CMS' national non-coverage decision for carotid stents, according to Coverage & Analysis Group Director Steve Phurrough. The CMS official observed that the FDA panel reviewing the product April 21 "was not very positive at all," and that the 6-5 vote in favor of approval is "not a ringing endorsement." (1"The Gray Sheet" April 26, 2004, p. 3) Phurrough's comments arose during the Schwab Soundview Capital Markets meeting in Washington, D.C. May 6...
Advertisement

Related Content

J&J Precise Panel Vote Nearly Split On Carotid Disease Subgroup Benefit
J&J Precise Panel Vote Nearly Split On Carotid Disease Subgroup Benefit
Advertisement
UsernamePublicRestriction

Register

MT020176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel